A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

This is thanks to exponential growth from compounding. You don’t have to be a Nobel Prize winner like Einstein to benefit from the power of compounding. Here’s how to open a compound interest ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Are you looking for prescription drugs like Ozempic, Wegovy, and Mounjaro online? You’re not alone. However, shopping for ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version in early 2025 ...

"FDA continues to monitor supply and demand for these products." Since the shortage began, specialty and compounding pharmacies have been allowed to sell off-brand versions of the weight loss drug.

Related: 1 in 8 U.S. Adults Have Taken Ozempic or Similar Drugs, According to a New Survey Since the shortage began, specialty and compounding ... stated that semaglutide, the active ingredient ...